SIGA Technologies Third Quarter 2026 Earnings Call - SIGA TECHNOLOGIES INC

Explicit Guidance:

• No new revenue, earnings, margin, or cash flow guidance was provided for FY2026 or future fiscal years.
• Management stated that results are subject to inherent quarter-to-quarter variability and should be viewed over a longer horizon rather than based on single-period results.
• Projected net income/loss figures provided are historical (approx. $6 million net income for 9 months ended Sept 30, 2026; approx. $3 million net loss for the quarter) with no forward-looking financial targets.

Business-Segment Outlook:

• TPOC (Therapeutic): Expectation to extend coverage across the full population (infants to adults) if the pediatric formulation yields successful Phase 1 results by year-end 2026.
• International Sales: A new five-year contract with Canada's Department of National Defense (CDND) is active, valued up to $15 million ($9 million firm over the first three years; $6 million optional). Deliveries for firm orders are expected to start in 2027, structured to deliver an equal number of courses in each of the first three fiscal years of the contract (potentially two deliveries in one calendar year due to fiscal year alignment).
• Backlog/Pipeline: Advanced-stage negotiations are underway with another international customer; no specific financial value or timing disclosed beyond "appropriate time."
• PEP Program: Supplemental New Drug Application (sNDA) filing for post-exposure prophylaxis (PEP) is now expected in 2028, delayed from prior expectations due to FDA-requested additional validation and laboratory work.
• Pediatric Program: Phase 1 study results expected by year-end 2026; outcomes will dictate next steps for stockpile inclusion.

Market and Competitive Outlook:

• Demand Trends: Management anticipates continued government investment in medical countermeasures stockpiles driven by geopolitical tensions and AI-driven biological threats.
• Pricing/Share: Increased focus on biodefense spending noted in Europe and the UK, with a strategic opportunity to shift paradigms from vaccine-centric to combined vaccine-and-antiviral approaches.
• Competitive Landscape: Acknowledgment that European preparedness has historically been vaccine-centric; SIGA views its role as evolving stockpiling conversations at country and regional levels.
• Regulatory Impact: Recent removal of the smallpox label for NPOX in Europe is not expected to materially change long-term opportunities, though it may affect timing due to additional discussions.

Macro / Industry Outlook:

• Geopolitics/Economy: Confidence remains high that national security for medical countermeasures is a priority for the U.S. government despite slower procurement timelines.
• Political Environment: Midterm election results are not expected to materially impact biodefense funding or the trajectory of the new U.S. government contract process beyond typical transition periods, citing historical bipartisan support.
• Procurement Timing: Anticipates that a new U.S. government procurement contract will be awarded, though specific timing and details remain uncertain.
• Regulation: FDA engagement remains highly engaged regarding the PEP program, with specific validation requirements extending the timeline.

Strategic Initiatives:

• Product Portfolio: Execution on pediatric formulation and PEP programs to create a comprehensive solution for governments.
• Market Expansion: Leveraging the new CDND contract to maintain a diverse revenue stream; advancing discussions with other international customers.
• Operational: Transitioning from the completed BARDA 19C contract to securing new long-term agreements.
• Personnel: Retention of Chief Scientific Officer Dennis Herbe in an advisory role post-retirement after three decades.
• Balance Sheet: Maintaining $116 million in cash with no debt to support execution of mission and operations.

Risks and Headwinds to Outlook:

• Procurement Uncertainty: Timing and details of future U.S. government contracts remain uncertain; the process to secure a new contract has progressed more slowly than in the past.
• Regulatory Timelines: FDA-mandated additional validation for the PEP program has delayed the sNDA filing to 2028.
• Revenue Variability: Business model exhibits inherent quarter-to-quarter variability, with product revenues recorded in a non-linear rhythm (e.g., most 9-month revenue recorded in Q2).
• Market Pace: Shifts in European stockpiling paradigms and regulatory label changes may delay sales timelines despite long-term opportunity.

Management Tone on the Future:

• Confidence: "Strong" confidence in the enduring case for smallpox preparedness and the critical role of TPOCs in national security plans.
• Resilience: Emphasis on the company's strong balance sheet and ability to navigate unpredictable procurement cycles.
• Hedges: Frequent caveats regarding the unpredictability of government procurement processes and the potential for results to differ due to regulatory or timing shifts.
• Sentiment: Cautiously optimistic; acknowledges delays in the PEP program and U.S. contract timeline as "disappointing" but not indicative of reduced program relevance.

Miscellaneous:

• Geography: Recent revenue includes sales to the U.S., Asia-Pacific region, and Europe; specific focus on Canada as a leader in international preparedness.
• Product: TPOX is approved in the U.S., Canada, EU, UK, and Japan, sold to >30 countries.
• Timeline: Fiscal year reference includes periods ending December 31, 2025, and September 30, 2026.